Clinical data on patients used in this study
| Sjögren's syndrome | Healthy controls | |
|---|---|---|
| Cohort characteristics | ||
| Number | n=31 | n=28 |
| Age in years (mean±SD) | 55±13 | 53±8 |
| Range | 18–72 | 36–63 |
| Female:male | 30:1 | 28:0 |
| Patients clinical features | ||
| Duration of disease in years (mean±SD) | 9±6 | – |
| Ro/SSA+ | 10/31 | – |
| La/SSB+ | 1/31 | |
| Ro/SSA+ and La/SSB+ | 15/31 | – |
| No Ro/SSA+ and La/SSB+ | 5/31 | |
| ANA+ | 27/31 | – |
| Other autoantibodies | 12/31 | |
| RF | 5/31 | |
| Anti-CCP | 3/31 | |
| Anti-RNP | 2/31 | |
| Anti-Sm | 1/31 | |
| Anti-native DNA | 1/31 | |
| Anticentromere | 1/31 | |
| ESR (mean±SD) | 33.7±27.9 | |
| CRP (mean±SD) | 6.4±17.7 | |
| IgG (mean±SD) | 16.4±5.9 | |
| IgA (mean±SD) | 2.7±1 | |
| IgM (mean±SD) | 1.29±0.8 | |
| Salivary secretion | ||
| Negative | 10/31 | |
| Positive | 17/31 | |
| Schirmer's test | ||
| Negative | 12/31 | |
| Positive | 16/31 | |
| GC+ | 5/15 | |
| GC− | 10/15 | |
| Focus score (range) | 0–5 | – |
| FS: 0 | 5/31 | |
| FS: 1 | 10/31 | |
| FS: 2 | 4/31 | |
| FS: 3 | 1/31 | |
| FS: 4 | 4/31 | |
| FS: 5 | 2/31 | |
| Not determined | 5/31 | |
| Treatment | ||
| Antimalarial | 7/31 | – |
| Oral steroids | 5/31 | – |
| Dose | 2/5: 2.5 mg/day | |
| 2/5: 5 mg/day | ||
| 1/5: 10 mg/day | ||
| Methotrexate | 1/31 | – |
| Dose | 20 mg/week | |
| Extraglandular manifestations | 11/31 | |
| Polyarthritis/RA | 2/31 | |
| Serositis | 1/31 | |
| Autoimmune hepatitis | 1/31 | |
| Goitre | 1/31 | |
| Hypothyroidism | 3/31 | |
| Interstitial lung disease | 1/31 | |
| MALT-lymphoma | 1/31 | |
| Fever | 1/31 | |
Fractions indicate the number of patients positive for the observed characteristics out of the total, not all clinical data were available for all patients. Focus score indicates the number of inflammatory foci containing more than 50 mononuclear cells per 4 mm2 biopsy tissue. Germinal centre (GC) ± indicates patient samples positive or negative for ectopic GC-like structures in biopsies. Other autoantibodies: rheumatoid factor (RF), anticyclic citrullinated peptide (anti-CCP), antiribonucleoprotein (anti-RNP). Whole saliva secretion has been measured per 15 minutes where >1.5 ml saliva are considered as negative, <1.5 ml as positive, decreased salivary flow. Schirmer's test determines the tear volume in mm/5 minutes, where >5 mm are considered as a negative, <5 mm as a positive result.
ANA, antinuclear antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FS, focus score; MALT, mucosa-associated lymphoid tissue; RA, rheumatoid arthritis.